2 completed, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Antiandrogen: new trials by email Literature Review of Antiandrogen trials Research Report on Antiandrogen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
| Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen - Prostate Cancer | Phase 2 | Completed | University of Washington | 32 | 2002-03-12 | 2018-08-07 |
| Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer LHRH agonist, antiandrogen, radiation therapy - Prostate Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 63 | 2000-09-01 | 2016-07-18 |
Prostatic Neoplasms (2) · Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Alliance for Clinical Trials in Oncology (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Washington (1)
United States (3)
Celestia Higano, MD (1) · Eric Winer, MD (1) · Lisa A Carey, MD (1) · Mark Hurwitz, MD (1)
U10CA031946 (1)